Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor that induced high overall response rates (ORR, 79%) and complete responses (CR, 20%) in a first-in-human dose escalation study (M12-175) in patients with relapsed/refractory (R/R) CLL. The addition of monthly rituximab (R; months 1 –6) in combination with VEN is being evaluated in an ongoing phase 1b dose-escalation study (M13-365) and as of 28 Oct 2015, the observed ORR is 86% and the CR rate is 47%.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Constantine Tam, Andrew W. Roberts, Shuo Ma, Danielle Brander, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Michael Choi, Leanne Lash, Maria Verdugo, Su Young Kim, Ming Zhu, John F. Seymour Source Type: research